Prostate-Specific Antigen Testing for Prostate Cancer Screening—Is the Message Getting Through?
Cet article analyse l'évolution de l'utilisation du dosage sérique du PSA après la révision 2017-2018 des recommandations de l'"US Preventive Services Task Force" sur le dépistage du cancer de la prostate
Since the discovery of prostate-specific antigen (PSA) more than 40 years ago and its subsequent wide adoption for the detection of prostate cancer, screening for the disease has been plagued with continuing controversies that remain largely unresolved. There is a profoundly engrained public perception embraced by many professionals that cancer detection as early as possible saves lives and therefore should be promoted at any cost, be it financial or in kind, such as the inevitable adverse effects caused by radical treatments. Although this may be true for some cancers, more than 3 decades of PSA testing among asymptomatic men across the globe, particularly in the Western world, has proved otherwise. Leapman et al illustrate this point in their article on the changes in the rates of PSA testing associated with recent updates in the US Preventive Services Task Force (USPSTF) recommendations on prostate cancer screening.
JAMA Oncology , éditorial, 2020